Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.
Biostatistics Collaboration Unit, Department of Biomedical Systems Informatics, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea.
Int J Mol Sci. 2023 Jan 25;24(3):2333. doi: 10.3390/ijms24032333.
Red blood cell (RBC) transfusion and albumin administration can affect kidney function. We aimed to evaluate the association between intraoperative 20% albumin administration and acute kidney injury (AKI), along with the duration of hospitalization and 30-day mortality in patients undergoing major abdominal surgery with RBC transfusion. This retrospective study included 2408 patients who received transfusions during major abdominal surgery. Patients were categorized into albumin ( = 842) or no-albumin ( = 1566) groups. We applied inverse probability of treatment weighting (IPTW), propensity score (PS) matching (PSM), and PS covariate adjustment to assess the effect of albumin administration on the outcomes. In the unadjusted cohort, albumin administration was significantly associated with increased risk of AKI, prolonged hospitalization, and higher 30-day mortality. However, there was no significant association between albumin administration and AKI after adjustment (OR 1.26, 95% CI 0.90-1.76 for the IPTW; OR 1.03, 95% CI 0.72-1.48 for the PSM; and OR 1.04, 95% CI 0.76-1.43 for the PS covariate adjustment methods). While albumin exposure remained associated with prolonged hospitalization after adjustment, it did not affect 30-day mortality. Our findings suggest that hyper-oncotic albumin can be safely administered to patients who are at risk of developing AKI due to RBC transfusion.
红细胞(RBC)输血和白蛋白给药会影响肾功能。我们旨在评估术中给予 20%白蛋白与急性肾损伤(AKI)的关联,以及接受 RBC 输血的大型腹部手术后患者的住院时间和 30 天死亡率。这项回顾性研究纳入了 2408 名在大型腹部手术中接受输血的患者。患者分为白蛋白组(=842)或无白蛋白组(=1566)。我们应用了逆概率治疗加权(IPTW)、倾向评分(PS)匹配(PSM)和 PS 协变量调整来评估白蛋白给药对结局的影响。在未调整的队列中,白蛋白给药与 AKI 风险增加、住院时间延长和 30 天死亡率升高显著相关。然而,在调整后,白蛋白给药与 AKI 之间无显著关联(IPTW 校正后的 OR 为 1.26,95%CI 为 0.90-1.76;PSM 校正后的 OR 为 1.03,95%CI 为 0.72-1.48;PS 协变量校正后的 OR 为 1.04,95%CI 为 0.76-1.43)。虽然白蛋白暴露在调整后仍与住院时间延长相关,但对 30 天死亡率没有影响。我们的研究结果表明,对于因 RBC 输血而有发生 AKI 风险的患者,可以安全地给予高渗白蛋白。